Clinical Value of High-Channel 12-Lead Holter in Assisting Early Identification of Arrhythmias in High-Risk Populations

AIMS/BACKGROUND: Cardiac arrhythmias are common in high-risk populations, often presenting paroxysmally and asymptomatically, leading to missed diagnoses and increased cardiovascular risks. This study aimed to retrospectively analyze the clinical value of high-channel 12-lead Holter electrocardiogram (ECG) in the early identification of arrhythmias in high-risk populations and to provide a reference for cardiovascular risk prevention and control in these groups. METHODS: Clinical data from 300 patients who met the criteria for high-risk populations and received diagnosis and treatment in Zibo Central Hospital from August 2023 to June 2024 were retrospectively collected. All patients underwent both routine 12-lead ECG examination and high-channel 12-lead Holter monitoring during the same period. The detection rates of atrial fibrillation, frequent ventricular premature beats (≥30 beats/h), frequent atrial premature beats (≥100 beats/24 h), and atrioventricular block were compared between the two modalities using appropriate statistical tests. Univariate logistic regression was performed to identify factors associated with positive arrhythmia detection. RESULTS: < 0.001). Similar patterns were observed for routine ECG, except for diabetes and BMI. CONCLUSION: In high-risk populations, the high-channel 12-lead Holter is highly valuable for screening paroxysmal and intermittent arrhythmias (especially atrial fibrillation and frequent ventricular premature beats). It can serve as an effective supplement to the routine ECG, providing a key basis for the early and accurate detection and intervention of arrhythmias in high-risk groups.